Hepatitis C Virus-Infected Responders and Relapsers to Treatment Show Similar Genetic Profiles of IL28B and IL10 Single Nucleotide Polymorphisms

Abstract EN

Genotype 1 of hepatitis C virus (HCV) is the most prevalent worldwide.

Pegylated-interferon and ribavirin therapy is still used in the developing world but has less efficiency in this genotype.

Single nucleotide polymorphisms (SNPs) rs12979860 and rs8099917 (IL28B) and rs1800896, rs1800871, and rs1800872 (IL10) are related to treatment outcome, but previous studies clustered nonresponse and relapse patients.

The aim of this study is to analyze the frequency of those SNPs in HCV genotype 1 for response, nonresponse, or relapse.

Patients were classified according to treatment outcome.

Genomic DNA was extracted by blood samples and SNPs were defined by PCR and sequencing.

Data analysis was performed with R project.

The frequency of rs12979860 CC was similar among responders (0.48) and relapsers (0.46) and lower among nonresponders (0.18).

The same trend was observed for rs8099917 TT.

rs12979860 CC showed a protective effect for relapsers compared to nonresponders (OR = 0.25) as it occurs with responders (OR = 0.17).

Haplotypes 12979860/C rs8099917/T were associated with protection against the nonresponder phenotype compared to responders (OR = 0.27) or relapsers (OR = 0.37).

Frequency of rs12979860 and rs8099917 is different between relapsers and nonresponders, but similar between relapsers and responders.